Zura Bio Limited Class A Ordinary Shares (ZURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zura Bio Limited Class A Ordinary Shares (ZURA) has a cash flow conversion efficiency ratio of -0.130x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.44 Million) by net assets ($118.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zura Bio Limited Class A Ordinary Shares (ZURA) defensive interval to measure how many days the company can operate on defensive assets alone.
Zura Bio Limited Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Zura Bio Limited Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zura Bio Limited Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zura Bio Limited Class A Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HansBiomed Corporation
KQ:042520
|
0.036x |
|
Hunan Copote Science Technology Co Ltd
SHG:600476
|
-0.072x |
|
LiveWire Group Inc.
NYSE:LVWR
|
-0.459x |
|
Soosan Industries Co. Ltd.
KO:126720
|
0.015x |
|
Hwacom Systems
TWO:6163
|
0.237x |
|
Firich Enterprises Co Ltd
TWO:8076
|
0.015x |
|
Alro Slatina
RO:ALR
|
0.049x |
|
Ege Gubre Sanayi AS
IS:EGGUB
|
0.021x |
Annual Cash Flow Conversion Efficiency for Zura Bio Limited Class A Ordinary Shares (2021–2024)
The table below shows the annual cash flow conversion efficiency of Zura Bio Limited Class A Ordinary Shares from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Zura Bio Limited Class A Ordinary Shares.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $160.02 Million | $-28.08 Million | -0.175x | +7.28% |
| 2023-12-31 | $79.55 Million | $-15.05 Million | -0.189x | -447.24% |
| 2022-12-31 | $-22.06 Million | $-1.20 Million | 0.054x | +746.14% |
| 2021-12-31 | $130.20 Million | $-1.10 Million | -0.008x | -- |
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more